Sampl.id provides a self‑sampling system for first‑void urine collection that uses a passive flow‑diversion geometry to capture a standardized, biomarker‑rich sample without clinic visits. The kit includes a pre‑filled preservation medium that stabilizes the sample at room temperature for up to seven days, enabling affordable, non‑invasive diagnostics for HPV, prostate cancer, STIs and other urogenital conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current urogenital diagnostic testing often requires invasive, clinician‑collected samples such as cervical swabs or digital rectal examinations, which create logistical barriers, discomfort, and cultural resistance, leading to low participation in screening programs.
Solution
Sampl.id offers a self‑sampling kit that captures a standardized first‑void urine (FVU) sample using a passive flow‑diversion geometry (Ini‑Stream). The collected urine is immediately mixed with a proprietary urine preservation medium (UPM) that stabilizes biomarkers at room temperature for up to seven days, eliminating the need for cold chain logistics. The kit is pre‑filled (Ini‑Stream 12P) or available empty for partner buffers (Ini‑Stream 12N), allowing seamless integration into existing diagnostic workflows. By providing a non‑invasive, at‑home collection method, Sampl.id enables reliable HPV, prostate‑cancer, STI, and emerging urogenital‑cancer testing without clinic visits, reducing costs and increasing user confidence and cultural inclusivity.
Target Audience
Primary customers are diagnostic manufacturers, public‑health screening programs, and research institutions that require reliable, non‑invasive sample collection for urogenital biomarkers, as well as global‑health organisations seeking culturally inclusive screening solutions.
Features
- Passive flow‑diversion geometry that isolates the initial urine stream, delivering a concentrated wash of urogenital biomarkers
- Pre‑filled collection tube (Ini‑Stream 12P) with proprietary urine preservation medium for immediate sample stabilization
- Optional empty tube (Ini‑Stream 12N) for partners to use their own preservation buffers
- UPM maintains biomarker integrity at 2–30 °C for up to 7 days, supporting room‑temperature transport and simplifying logistics
- Compatible with a range of molecular assays for HPV, prostate cancer, STI, DNA‑methylation triage, and other urogenital cancer markers
- Fully non‑invasive, self‑collected workflow that integrates into diagnostic assay pipelines and national screening programs
- Demonstrated higher user preference (~90 % confidence) and lower per‑screen cost compared with clinician‑collected or vaginal self‑sampling methods